Pharma HCV Testing

Monogram Biosciences has a legacy of developing state-of-the-art, highly reproducible, high-throughput assays in a clinical reference laboratory setting. To meet the growing demand for hepatitis C virus (HCV) assays, Monogram has developed its technology platforms to enable evaluation of HCV antiviral drug resistance and other HCV characteristics.

Please contact Monogram about technical and pricing information and validation summaries for the following assays:

HCV Genotyping

Antiviral Drug Resistance

Questions?

Please call 678-225-0222 or email mngquickresponse@labcorp.com

For all Canadian inquiries, contact:
Dynacare Genetics and Specialty Services
Toll-free: 1-888-988-1888
Fax: 1-450-663-4428
DynacareGenetics@dynacare.ca
Monday through Friday, 8:30am – 8:00pm EST

HCV Posters and Publications

Poster

Cross-sectional Assessment of 1500 Clinical Samples Submitted for HCV NS3/4A Protease Inhibitor Drug Resistance Testing in the US (PDF)

Poster

Phenotypic Detection of HCV Polymerase Inhibitor Resistant Subpopulationsis Dependent on Relative Resistance and Replication Capacity; IC95 Values Improve Detection (PDF)

Poster

Validation of an HCV NS3/4A Sequencing Assay for Evaluating Resistance to Boceprevir, Telaprevir and Protease Inhibitor Candidates in a Clinical Reference Laboratory Setting (PDF)

Poster

Analytical Validation of an HCV Replicon-based Phenotypic Assay for Evaluating Replication Capacity and Susceptibility of Genotype 1a/1b Patient viruses to Polymerase Inhibitors (PDF)

Poster

Development of Recombinant Replicon Report Assays for Characterization of HCV NS5A and NS3/4A Protease Inhibitors (PDF)

Poster

A Newly Modified HCV Replicon Assay with an Expanded Capability to Evaluate the Susceptibility of Genotype 1a and 1b Patient Viruses to Polymerase Inhibitors (PDF)

Managing Your Health

Diseases & Therapeutic Areas

Treatment Modalities & Methods

Scientific Lab Disciplines

Labs

Industries

Pharma HCV Testing

Questions?

HCV Posters and Publications

Cross-sectional Assessment of 1500 Clinical Samples Submitted for HCV NS3/4A Protease Inhibitor Drug Resistance Testing in the US (PDF)

Phenotypic Detection of HCV Polymerase Inhibitor Resistant Subpopulationsis Dependent on Relative Resistance and Replication Capacity; IC95 Values Improve Detection (PDF)

Validation of an HCV NS3/4A Sequencing Assay for Evaluating Resistance to Boceprevir, Telaprevir and Protease Inhibitor Candidates in a Clinical Reference Laboratory Setting (PDF)

Analytical Validation of an HCV Replicon-based Phenotypic Assay for Evaluating Replication Capacity and Susceptibility of Genotype 1a/1b Patient viruses to Polymerase Inhibitors (PDF)

Development of Recombinant Replicon Report Assays for Characterization of HCV NS5A and NS3/4A Protease Inhibitors (PDF)

A Newly Modified HCV Replicon Assay with an Expanded Capability to Evaluate the Susceptibility of Genotype 1a and 1b Patient Viruses to Polymerase Inhibitors (PDF)